Colorectal cancer is rising fast, especially among younger populations, and one of the biggest problems is not treatment. It is missed screening.

Recorded live at ViVE in the Diagnostic Zone, Eliad sits down with Jay Sidgreaves of New Day Diagnostics to talk about ColoHealth, an FDA-approved blood-based colorectal cancer screening test designed to help close one of the most urgent gaps in healthcare: getting more people screened before it is too late.

Jay explains why FDA approval matters, why accessibility matters even more, and how diagnostics is moving toward a future where consumers play a much more active role in their care. This conversation also gets into where healthcare is headed next, from blood-based testing and digital platforms to AI-enabled patient education and a more consumer-driven diagnostic experience.

This is not just a conversation about one test. It is a conversation about where diagnostics, prevention, and patient behavior are heading next.

What this episode covers:

• Why colorectal cancer screening remains a major gap in healthcare
• Why blood-based testing could improve access and participation
• What FDA approval signals to patients, providers, and markets
• How consumer-driven diagnostics are changing healthcare
• Why digital health and AI will reshape the patient experience